Opendata, web and dolomites

SenPET SIGNED

Innovative cancer management: First in human senescence imaging

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 SenPET project word cloud

Explore the words cloud of the SenPET project. It provides you a very rough idea of what is the project "SenPET" about.

imagelink    biopsies    erc    distinction    synthesis    gold    tool    cancer    senescent    radiosynthesis    compliant    techniques    correlated    shown    plays    gastrointestinal    arrest    stable    physiological    preclinical    utmost    senpet    tumor    industrial    progression    quantification    protected    medicine    clear    histological    senescence    patent    setting    galactosidase    paperwork    detection    convincing    biomarker    larger    desirable    approval    staining    human    translate    collected    collection    proof    vivo    automated    suffering    vitro    clinical    tumors    cellular    patients    tracer    validated    treatment    termed    elimination    standard    personalized    good    scope    models    outcome    irreversible    gmp    care    manufacturing    chemotherapy    exceeds    radiolabeled    markers    cells    encouraged    invasive    therapies    senolytics    marker    szlig    first    patient    pet    data    murine    protocol    inducing    accomplished    ex    perform    team    promotion    predictive    reproducible   

Project "SenPET" data sheet

The following table provides information about the project.

Coordinator
EBERHARD KARLS UNIVERSITAET TUEBINGEN 

Organization address
address: GESCHWISTER-SCHOLL-PLATZ
city: TUEBINGEN
postcode: 72074
website: www.uni-tuebingen.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-04-01   to  2020-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EBERHARD KARLS UNIVERSITAET TUEBINGEN DE (TUEBINGEN) coordinator 150˙000.00

Map

 Project objective

The irreversible growth arrest, termed cellular senescence, plays a key role in tumor progression and promotion, as well as in many other physiological processes. It has been shown to be a predictive marker for the long term outcome of cancer treatment and novel therapies aiming at the elimination of senescent cells are under development (i.e. senolytics). Therefore, techniques for the detection of senescence are of utmost importance. However, in the current clinical setting this is only possible with histological staining after collection of invasive biopsies and a tool for non-invasive assessment and quantification of senescence is highly desirable towards improved patient care and personalized medicine.

Within our current ERC project ImageLink we have developed a stable and reproducible synthesis protocol for a novel radiolabeled PET-tracer targeting ß-galactosidase, the “gold-standard” biomarker of senescence. The tracer was validated in several in vitro and in vivo human and murine tumor models. A clear distinction between senescent and non-senescent tumors was possible and the convincing results have encouraged us to translate our preclinical findings into a clinical setting. However, this step exceeds the scope of our current ERC project.

Within the planned project SenPET we will establish an automated radiosynthesis of the tracer that is compliant with good manufacturing practice (GMP) and all necessary paperwork with the authorities for approval of a clinical study will be accomplished. Finally we will perform the first clinical proof of concept study of a senescence PET tracer in 10 patients suffering from gastrointestinal tumors. PET data with our novel tracer will be collected before and after a senescence inducing chemotherapy treatment and correlated with ex vivo markers of senescence. Since our tracer is protected by patent applications, the results of this study will help us to team up with industrial partners to perform larger clinical studies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENPET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SENPET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

FICOMOL (2019)

Field Control of Cold Molecular Collisions

Read More  

NanoPD_P (2020)

High throughput multiplexed trace-analyte screening for diagnostics applications

Read More  

In Motion (2018)

Investigation and Monitoring of Time-varying Environments on Macro and Nano Scales

Read More